Gudina, E.K.* et al. Tailoring COVID-19 vaccination strategies in high-seroprevalence settings: Insights from Ethiopia. Vaccines 12:745 (2024)
Liao, B.H.* et al. SARS-CoV-2 neutralization capacity in hemodialysis patients with and without a fifth vaccination with the updated comirnaty original/omicron BA.4-5 vaccine. Vaccines 12:308 (2024)
Azzini, A.M.* et al. How european research projects can support vaccination strategies: The case of the ORCHESTRA project for SARS-CoV-2. Vaccines 11:8 (2023)
Reguraman, N.* et al. Assessing the efficacy of VLP-based Vaccine against Epstein-Barr Virus using a rabbit model. Vaccines 11:14 (2023)
Stephan, A.-S. et al. Evaluation of the effect of CD70 co-expression on CD8 T cell response in protein-prime MVA-boost vaccination in mice. Vaccines 11:17 (2023)
Cheng, C.C.* et al. Improved SARS-CoV-2 neutralization of delta and omicron BA.1 variants of concern after fourth vaccination in hemodialysis patients. Vaccines 10:1328 (2022)
Michaelides, S.* ; Obeck, H.* ; Kechur, D.* ; Endres, S. & Kobold, S. Migratory engineering of T cells for cancer therapy. Vaccines 10:1845 (2022)
Kosinska, A. et al. Immunogenicity and antiviral response of therapeutic hepatitis B vaccination in a mouse model of hbeag-negative, persistent hbv infection. Vaccines 9:841 (2021)
Becker, P.D.* et al. Gene expression driven by a strong viral promoter in MVA increases vaccination efficiency by enhancing antibody responses and unmasking CD8⁺ T cell epitopes. Vaccines 2, 581-600 (2015)